argenx SE (NASDAQ:ARGX) headquartered in Breda, will host a conference call for the investment community to discuss the 3Q20 financial results on 22nd October 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.argenx.com
Earnings Expectation
argenx SE is reporting third quarter financial results on Thursday 22nd October 2020, before market open.
According to analysts surveyed by Thomson Reuters, ARGX is expected to report 3Q20 loss of $ 2.82 per share from revenue of $ 16.85 million.
For the full year, analysts anticipate top line of $ 81.97 million, while looking forward to loss of $ 11.22 per share bottom line.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The companys lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis.
